tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age. In the clinical trial, the vaccine candidates were compared to a licensed influenza vaccine and the compan...
Lead formulations evaluated in the Phase 1/2 study demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains Safety profile of the mRNA-based combination vaccine candidates consistent with the companies’ COVID-19 vaccine T
To make an updated mRNA vaccine, you need two ingredients: the genetic sequence of the spike protein from a new variant of concern and a DNA template that would be used to build the mRNA. In most organisms, DNA provides the instructions for making mRNA. Sinc...
The FDA-approved COMIRNATY (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older when prepared according to their respective instructions for use can be used interchangeably.2 COMIRNATY (COVID-19 Vaccine, mRNA) and the ...
When Moderna, another coronavirus mRNA vaccine that is now approved and that works very similar to the Pfizer vaccine, was just finishing its Phase I trial, The Independent wrote about the vaccine and described it this way: “It uses a sequence of genetic RNA material produced in a lab that...
Pfizer Inc. and BioNTech SE announced top-line results from their Phase 3 clinical trial to evaluate the companies' combined mRNA vaccine candidate
Discussions with regulatory authorities are ongoing regarding an additional registration-enabling study using an mRNA vaccine with a variant sequence; this would provide a flexible solution for rapidly adapting the vaccine for use against the B.1.351 lineage or other new strains that m...
mRNA-based vaccinesTo prevent the invasion and transmission of SARS-CoV-2, mRNA-based vaccines, non-replicating viral vector vaccines, and inactivated vaccines have been developed. The European Medicines Agency (EMA) authorized the use of the anti-SARS-CoV-2 vaccine in January 2021, the date ...
1 RESEARCH LETTER mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients? Veerle P. W. M. Wijtvliet 1,2 , Kevin K. Ariën 3,4 , Steven Abrams 5,6 , Marie M. Couttenye 1,2 , Fabienne Mestrez 7 , Joachim Mari...
By contrast, mRNA vaccines like Pfizer's (and Moderna's) can be updated much more quickly. Pfizer just needs to rework its RNA sequence to cover variants, which is a minor modification. Nothing changes about the delivery system of the vaccine, so reapproval will likely be much easier. Regu...